Paroxetine and imipramine: A 12-week, double-blind, multicentre study in hospitalized depressed patients

North of England evidence-based guideline development project: summary version of guidelines for the choice of antidepressants for depression in primary care

“…Analysis of the comparative efficacy of SSRIs and tricyclic antidepressants in in-patients (judged likely to be a more severely affected group) provided a slightly larger estimate of effect favouring tricyclic antidepressants, though again non-significant. The overall estimate of effect in this grouping of studies 8,16,27,35,44,47,67,69,73,74,77,80,81,82,86,88,91,94,98,99,105,108,111,118,120,127 (using a random effects model) was 0.10 (95% CI -0.072 to 0.272, Q = 49.1, d.f. = 22, P = 0.008).…”

Selective Serotonin Reuptake Inhibitors

“…In the other two studies, which did not include a placebo control, no difference was found between TCA and SSRI. Four studies and one meta-analysis of European antidepressant trials also found no difference in efficacy between various SSRIs and several tertiary amine TCAs in patients hospitalized for major depression (Ginestet 1989;Tignol et al 1992;Beasley et al 1993a;Arminen et al 1994;Ottevanger 1995). Finally, two small studies have found that fluoxetine and fluvoxamine had antidepressant efficacy superior to placebo in patients with melancholia (Feighner et al 1989;Heiligenstein et al 1993), while another larger study did not find a difference between paroxetine and amitriptyline in such patients (Stuppaeck et al 1994).…”